Literature DB >> 10594482

Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine.

T Dervieux1, Y Médard, V Baudouin, A Maisin, D Zhang, F Broly, C Loirat, E Jacqz-Aigrain.   

Abstract

AIMS: Azathioprine is a prodrug commonly used in combination therapy to prevent allograft rejection after renal transplantation. After conversion to 6-mercaptopurine, the drug is metabolized into 6-thioguanine nucleotides (6-TGN) and catabolized by thiopurine methyltransferase (TPMT), an enzyme under monogenic control. The aim of this study was to evaluate the inter- and intraindividual variability of red blood cell thiopurine methyltransferase and 6-TGN concentrations and their relationship to the clinical effects of azathioprine in paediatric patients.
METHODS: In the present study, the inter- and intraindividual variations in red blood cell TPMT activity and 6-TGN concentrations and their relationship to the actions of azathioprine were evaluated during the first year after renal transplantation in 22 paediatric patients.
RESULTS: 6-TGN concentration reached steady-state values after 6 months and correlated negatively with TPMT activity (P=0.004). Initial TPMT activity (median: 20.8 nmol h-1 ml-1, range 7.8-34.6) and 6-TGN concentration at steady-state (median: 80 pmol 8 x 10(8-1) cells, range not detected to 366) were not related to the occurrence of rejection episodes during the period of the study. In contrast, TPMT activity and the percentage difference in TPMT activity from the day of transplantation determined at month 1 were higher in the patients with rejection episodes by comparison with those that did not reject during the first 3 months or the first year following transplantation (P<0.005).
CONCLUSIONS: We report a relationship between TPMT activity and occurrence of rejection in paediatric kidney transplant patients undergoing azathioprine therapy. These data suggest a link between high red blood cell TPMT activity and poor clinical outcome probably caused by rapid azathioprine catabolism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594482      PMCID: PMC2014314          DOI: 10.1046/j.1365-2125.1999.00087.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

Review 1.  The purine path to chemotherapy.

Authors:  G B Elion
Journal:  Science       Date:  1989-04-07       Impact factor: 47.728

2.  Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells.

Authors:  S Bergan; H E Rugstad; B Klemetsdal; T Giverhaug; O Bentdal; G Sødal; A Hartmann; J Aarbakke; O Stokke
Journal:  Ther Drug Monit       Date:  1997-06       Impact factor: 3.681

3.  Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity.

Authors:  H L Tai; E Y Krynetski; E G Schuetz; Y Yanishevski; W E Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies.

Authors:  L C Woodson; J H Dunnette; R M Weinshilboum
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

5.  Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide.

Authors:  R A Lysaa; T Giverhaug; H L Wold; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

6.  Thiopurine methyltransferase activity: new high-performance liquid chromatographic assay conditions.

Authors:  Y Medard; S Nafa; E Jacqz-Aigrain
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-10-24

7.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

8.  Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors.

Authors:  P A Pazmiño; S L Sladek; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  1980-09       Impact factor: 6.875

9.  Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population.

Authors:  C Spire-Vayron de la Moureyre; H Debuysere; B Mastain; E Vinner; D Marez; J M Lo Guidice; D Chevalier; S Brique; K Motte; J F Colombel; D Turck; C Noel; R M Flipo; A Pol; M Lhermitte; J J Lafitte; C Libersa; F Broly
Journal:  Br J Pharmacol       Date:  1998-10       Impact factor: 8.739

10.  Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?

Authors:  E Schütz; J Gummert; F W Mohr; V W Armstrong; M Oellerich
Journal:  Ther Drug Monit       Date:  1996-06       Impact factor: 3.681

View more
  8 in total

Review 1.  Pharmacogenomics: personalizing pediatric heart transplantation.

Authors:  Sara L Van Driest; Steven A Webber
Journal:  Circulation       Date:  2015-02-03       Impact factor: 29.690

Review 2.  Immunosuppressive drugs in paediatric liver transplantation.

Authors:  I D van Mourik; D A Kelly
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.

Authors:  G Zaza; S Granata; F Sallustio; G Grandaliano; F P Schena
Journal:  Clin Exp Immunol       Date:  2009-11-24       Impact factor: 4.330

Review 4.  Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine.

Authors:  Gianluigi Zaza; Simona Granata; Paola Tomei; Alessandra Dalla Gassa; Antonio Lupo
Journal:  Int J Mol Sci       Date:  2015-02-17       Impact factor: 5.923

Review 5.  Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases.

Authors:  Anna Gluba-Brzózka; Beata Franczyk; Robert Olszewski; Maciej Banach; Jacek Rysz
Journal:  Int J Mol Sci       Date:  2017-06-10       Impact factor: 5.923

Review 6.  Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Authors:  Rita Diehl; Fabienne Ferrara; Claudia Müller; Antje Y Dreyer; Damian D McLeod; Stephan Fricke; Johannes Boltze
Journal:  Cell Mol Immunol       Date:  2016-10-10       Impact factor: 11.530

Review 7.  Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review.

Authors:  Cho-Hsun Hsieh; Yi-Wei Huang; Tsen-Fang Tsai
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-05

8.  TPMT and NUDT15 testing for thiopurine therapy: A major tertiary hospital experience and lessons learned.

Authors:  Liuh Ling Goh; Chia Wei Lim; Khai Pang Leong; Kiat Hoe Ong
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.